AMGN vs NVO

Amgen and Novo Nordisk A/S, both Healthcare

Novo Nordisk A/S is the larger company at $211B against $182B. Over the past year AMGN returned +37% against -13% for NVO. Ryufin's sector-relative Smart Score puts NVO ahead, 9/10 against 7/10.

Amgen and Novo Nordisk A/Scompared on valuation, return and Ryufin’s Smart Score
Figure	AMGN	NVO
Last close	$393	$45.17
Market cap	$182B	$211B
Trailing P/Elower is cheaper for the same earnings, not automatically better	24.4	n/a
Dividend yield	2.5%	n/a
1-year return	+37%	-13%
5-year return	+102%	-0.2%
Ryufin Smart Scoresector-relative, 1–10	7/10	9/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Amgen

Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.

AMGN overview revenue and segments valuation

Novo Nordisk A/S

NVO overview revenue and segments valuation

Open these two in the interactive comparison to add more names, change the period or see the correlation.